A detailed history of Bessemer Group Inc transactions in Biogen Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 3,331 shares of BIIB stock, worth $578,894. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,331
Previous 3,054 9.07%
Holding current value
$578,894
Previous $657,000 17.5%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $52,774 - $65,571
277 Added 9.07%
3,331 $772,000
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $9,116 - $11,511
43 Added 1.43%
3,054 $657,000
Q4 2023

Feb 09, 2024

SELL
$222.59 - $267.94 $457,422 - $550,616
-2,055 Reduced 40.56%
3,011 $779,000
Q3 2023

Nov 13, 2023

SELL
$253.3 - $285.89 $84,348 - $95,201
-333 Reduced 6.17%
5,066 $1.3 Million
Q2 2023

Aug 10, 2023

BUY
$275.25 - $318.06 $292,866 - $338,415
1,064 Added 24.54%
5,399 $1.54 Million
Q1 2023

May 10, 2023

SELL
$256.56 - $292.34 $14,110 - $16,078
-55 Reduced 1.25%
4,335 $1.21 Million
Q4 2022

Feb 13, 2023

SELL
$252.44 - $306.72 $42,914 - $52,142
-170 Reduced 3.73%
4,390 $1.22 Million
Q3 2022

Nov 09, 2022

BUY
$194.69 - $268.46 $171,911 - $237,050
883 Added 24.01%
4,560 $1.22 Million
Q2 2022

Aug 10, 2022

SELL
$187.54 - $223.02 $1,875 - $2,230
-10 Reduced 0.27%
3,677 $750,000
Q1 2022

May 12, 2022

BUY
$193.77 - $244.14 $165,479 - $208,495
854 Added 30.14%
3,687 $777,000
Q4 2021

Jan 27, 2022

BUY
$223.92 - $287.77 $155,624 - $200,000
695 Added 32.51%
2,833 $679,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $77,256 - $100,750
-273 Reduced 11.32%
2,138 $606,000
Q2 2021

Aug 06, 2021

BUY
$259.0 - $414.71 $67,081 - $107,409
259 Added 12.04%
2,411 $834,000
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $447,999 - $524,857
-1,844 Reduced 46.15%
2,152 $602,000
Q4 2020

Feb 09, 2021

SELL
$236.26 - $355.63 $209,562 - $315,443
-887 Reduced 18.17%
3,996 $978,000
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $802,253 - $926,301
-3,030 Reduced 38.29%
4,883 $1.39 Million
Q2 2020

Aug 05, 2020

BUY
$258.66 - $342.55 $1.06 Million - $1.4 Million
4,081 Added 106.5%
7,913 $2.12 Million
Q1 2020

Apr 30, 2020

SELL
$268.85 - $341.04 $72,320 - $91,739
-269 Reduced 6.56%
3,832 $1.21 Million
Q4 2019

Feb 04, 2020

BUY
$220.06 - $304.07 $106,068 - $146,561
482 Added 13.32%
4,101 $1.22 Million
Q3 2019

Nov 07, 2019

SELL
$217.44 - $243.88 $41,313 - $46,337
-190 Reduced 4.99%
3,619 $843,000
Q2 2019

Jul 19, 2019

BUY
$219.29 - $241.72 $355,688 - $392,069
1,622 Added 74.17%
3,809 $891,000
Q1 2019

May 13, 2019

BUY
$216.71 - $338.96 $185,070 - $289,471
854 Added 64.07%
2,187 $518,000
Q4 2018

Feb 12, 2019

BUY
$278.5 - $352.75 $106,108 - $134,397
381 Added 40.02%
1,333 $401,000
Q3 2018

Nov 06, 2018

SELL
$293.51 - $383.83 $11,740 - $15,353
-40 Reduced 4.03%
952 $336,000
Q2 2018

Jul 25, 2018

SELL
$257.52 - $306.91 $20,601 - $24,552
-80 Reduced 7.46%
992 $288,000
Q1 2018

May 10, 2018

SELL
$260.13 - $367.91 $4,942 - $6,990
-19 Reduced 1.74%
1,072 $293,000
Q4 2017

Jan 30, 2018

BUY
$307.64 - $344.58 $10,152 - $11,371
33 Added 3.12%
1,091 $347,000
Q3 2017

Nov 03, 2017

BUY
$281.15 - $329.69 $297,456 - $348,812
1,058
1,058 $331,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.